We read with interest the recently published monograph by Kearon 1 describing the natural progression and clinical treatment of venous thromboembolism, including deep vein thrombosis (DVT). In addition to noting that anticoagulation is the standard of care for symptomatic venous thromboembolism, Kearon reports that systemic thrombolytic therapy accelerates the rate of lysis of DVT. However, the author fails to discuss more recent findings suggesting that catheter-directed thrombolysis offers a more successful route of administration for thrombolytic agents such as streptokinase (SK), urokinase (UK), and recombinant tissue plasminogen activator (rt-PA).
Response
Drs Grunwald and Hofmann are mistaken that my review, Natural history of venous thromboembolism, 1 included a description of clinical treatment of venous thromboembolism. There is no description of treatment of venous thromboembolism in my review, nor was there meant to be. However, as much of what is known about the natural history of venous thromboembolism has been observed in patients who have been diagnosed and treated, and as the likelihood of progression and extent of resolution of treated venous thromboembolism is clinically important, this was described.
Drs Grunwald and Hofmann conclude that, "at institutions with the capability to perform catheter-directed thrombolysis, it should be front-line therapy for symptomatic DVT." Although this issue is unrelated to my review, as I have been invited to reply to their letter, I suggest that there is currently inadequate evidence to support such a recommendation. [2] [3] [4] Consequently, while I agree that there is a need to evaluate catheter-directed thrombolysis for treatment of deep vein thrombosis in randomized trials, I propose that anticoagulant therapy alone is the appropriate comparator rather than systemic thrombolytic therapy. Clinically important outcomes, including the post thrombotic syndrome, should be the main outcomes for such trials rather than radiologic assessments of the extent of residual thrombosis.
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